Study identifier:RDEA594-132
ClinicalTrials.gov identifier:NCT02127775
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1, Randomized, Open-Label, Crossover Study to Assess the Bioequivalence of Lesinurad Tablets from Two Manufacturing Sites in Healthy Adult Male Subjects
Healthy
Phase 1
Yes
Lesinurad 400 mg (manufactured at Site 1), Lesinurad 400 mg (manufactured at Site 2)
Male
54
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Sept 2014 by Ardea Biosciences, Inc.
Ardea Biosciences, Inc.
-
This study will assess the bioequivalence of lesinurad tablets manufactured at two different sites.
This study is intended to evaluate the clinical comparability of lesinurad tablets manufactured at the 2 different sites by assessing relevant clinical Pharmacokinetics (PK) parameters.
Location
Location
Austin, TX, United States, 78744
Arms | Assigned Interventions |
---|---|
Experimental: Sequence B Day 1: Lesinurad 400 mg (manufactured at Site 2); Day 5: Lesinurad 400 mg (manufactured at Site 1) | - |
Experimental: Sequence A Day 1: Lesinurad 400 mg (manufactured at Site 1); Day 5: Lesinurad 400 mg (manufactured at Site 2) | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.